Atara Biotherapeutics Inc
NASDAQ:ATRA
Atara Biotherapeutics Inc
Interest Income Expense
Atara Biotherapeutics Inc
Interest Income Expense Peer Comparison
Competitive Interest Income Expense Analysis
Latest Figures & CAGR of Competitors
Company | Interest Income Expense | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
Atara Biotherapeutics Inc
NASDAQ:ATRA
|
Interest Income Expense
$141k
|
CAGR 3-Years
-61%
|
CAGR 5-Years
-53%
|
CAGR 10-Years
N/A
|
|
Abbvie Inc
NYSE:ABBV
|
Interest Income Expense
-$1.8B
|
CAGR 3-Years
8%
|
CAGR 5-Years
-7%
|
CAGR 10-Years
-19%
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Interest Income Expense
-$757m
|
CAGR 3-Years
35%
|
CAGR 5-Years
0%
|
CAGR 10-Years
-10%
|
|
Amgen Inc
NASDAQ:AMGN
|
Interest Income Expense
-$2.6B
|
CAGR 3-Years
-38%
|
CAGR 5-Years
-27%
|
CAGR 10-Years
-16%
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Interest Income Expense
$563.1m
|
CAGR 3-Years
78%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Interest Income Expense
$172.2m
|
CAGR 3-Years
7%
|
CAGR 5-Years
65%
|
CAGR 10-Years
N/A
|
See Also
What is Atara Biotherapeutics Inc's Interest Income Expense?
Interest Income Expense
141k
USD
Based on the financial report for Dec 31, 2023, Atara Biotherapeutics Inc's Interest Income Expense amounts to 141k USD.
What is Atara Biotherapeutics Inc's Interest Income Expense growth rate?
Interest Income Expense CAGR 5Y
-53%
Over the last year, the Interest Income Expense growth was -93%. The average annual Interest Income Expense growth rates for Atara Biotherapeutics Inc have been -61% over the past three years , -53% over the past five years .